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I. INTRODUCTION 
From families trying to make ends meet to a state government 
working to balance its budget, rising health care costs pose a 
significant and daunting public policy challenge.  Minnesota 
Governor Tim Pawlenty’s Health Cabinet estimates that health care 
 
       †     Kevin Goodno, an attorney and the Commissioner of the Department of 
Human Services for the State of Minnesota, was charged by Governor Pawlenty 
with the development and operation of the Minnesota RxConnect program. 
     ††      General Counsel to Minnesota Governor Tim Pawlenty. 
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costs in Minnesota increase $70 each second.1  Every hour, health 
care in Minnesota costs a quarter of a million dollars more than it 
did last year.2 
The escalating cost of health care is one of the reasons 
Minnesota faced a projected $4.2 billion budget shortfall when 
Governor Pawlenty took office on January 6, 2003.3  The budget of 
the Department of Human Services, which is one quarter of the 
state budget, was projected to increase by 22% over the previous 
biennium largely due to rising health care costs.4  In addition, the 
state as an employer was experiencing a 17% increase in the cost of 
providing health care insurance to its own state employees.5 
Besides the direct impacts on the state, increased health care 
costs incurred by the private sector impact the state in indirect 
ways.  As employers are forced to spend more on non-taxable 
health care benefits for their workers, they spend less on salaries, 
which are taxable.  This in turn negatively impacts the revenue the 
state generates from income and sales taxes, making the budget 
challenge even worse. 
Despite all these pressures, Minnesota has consistently had one 
of the lowest rates of uninsured individuals in the country.6  This 
has been attributed to the generous state health care programs and 
to the fact that more of Minnesota’s employers, as compared to 
their counterparts in other states, provide health care coverage for 
their employees.7  This is the good news.  The bad news is that if 
health care costs continue to escalate, state government and private 
employers will be forced to reduce coverage, which will increase 
the number of uninsured in the state. 
In addition to appointing the Minnesota Citizens Forum on 
 
 1. State of Minnesota, Governor’s Health Cabinet: Minnesota Department of 
Employee Relations, at http://maximumstrengthhealthcare.com (last visited Feb. 5, 
2005). 
 2. Id. 
 3. Minnesota Department of Human Services, Office of Budget 
Management, at http://www.dhs.state.mn.us (last visited Jan. 30, 2005). 
 4. Id. 
 5. Minnesota Department of Employee Relations, at 
http://www.doer.state.mn.us (last visited Feb. 5, 2005). 
 6. Minnesota Health Department, Minnesota’s Uninsured: Findings from the 
2001 Health Access Survey, (April 2002), available at http://www.health.state.mn.us 
(hereinafter Minnesota’s Uninsured); see also Minnesota Department of Health, 
Health Economics Program Issue Brief: 2002 Minnesota Distribution of Insurance Coverage, 
(April 2004), available at http://www.health.state.mn.us/divs/hpsc/ 
hep/issbrief/2004-03.pdf. 
 7. Minnesota’s Uninsured, supra note 6. 
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Health Care Costs to address the daunting task of controlling 
health care costs,8 Governor Pawlenty directed his state agencies to 
develop their own strategies to address health care costs.9  A result 
of this directive was a variety of initiatives to control the high cost of 
prescription medicines. 
As advances in prescription medicines have improved length 
and quality of life, a hugely disparate international pricing system 
has evolved in which pharmaceutical companies charge wildly 
different prices for the same product in different countries.  The 
cost for individuals, particularly seniors with no prescription 
medicine coverage, has risen so significantly that it has too often 
forced choices between buying medicines and meeting other basic 
needs. 
In the United States, about $160 billion is spent on 
prescription medicines each year, with Minnesotans spending 
about $3 billion.10  The costs of prescription medicines receive so 
much attention in large part because, although prescription 
medicine costs constitute only 10.5% of total health care spending, 
they account for 23% of the total out-of-pocket costs that people 
incur when purchasing health care.11  Minnesota has been a leader 
in controlling prescription medicine costs.  It has aggressively used 
purchasing pools when possible, and encouraged the use of lower 
cost, generic prescription medicines when appropriate. 
Even with these efforts to control costs, prescription medicines 
were still becoming too costly for many Minnesotans to afford.  
Busloads of senior citizens headed north for Canada.12  Others used 
Internet pharmacies, some of which were unsafe.13  The need for 
lower cost prescription medicine alternatives and a desire to 
protect the safety of Minnesotans who seek them caused Governor 
Pawlenty, in September of 2003, to direct the Minnesota 
Department of Human Services to examine the feasibility of 
 
 8. Minnesota Citizens Forum on Health Care Cost, available at 
http://www.mncitizensforum.org (last updated Feb. 27, 2004). 
 9. Id. 
 10. Warren Wolfe, Modest Start for State Drug Sites, STAR TRIB., July 21, 2004, 
available at www.startribune.com/viewers/story.php?template=a&story=4886132. 
 11. Donald L. Barlett & James B. Steele, Why We Pay So Much for Drugs, TIME, 
Feb. 2, 2004, at 44, 47. 
 12. See, e.g., Rx Express, Mark Dayton, United States Senator, available at 
http://dayton.senate.gov/issues/health/rx-express.cfm. 
 13. Press Release, Tim Pawlenty, Governor of Minnesota, Governor Pawlenty 
Takes Action on Problem of Escalating Prescription Drug Costs (Sept. 24, 2003) 
(on file with author). 
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importing prescription medicines from Canada and other 
international sources.14  He directed the Commissioner of Human 
Services to examine methods to address the needs of Minnesota 
state employees, the citizens served through the state’s public 
assistance programs, and the state’s citizens at large.15 
In response to this directive, a three-phase plan was 
developed.16  The plan called for the development of a website to 
empower Minnesota consumers to purchase mail-order 
prescription medicines for personal use from approved Canadian 
pharmacies; the option for Minnesota state employees to 
voluntarily obtain prescriptions for maintenance medications from 
Canadian pharmacies; and the establishment of a pilot project that 
allows Minnesotans to purchase Canadian prescription medicines 
from their local pharmacies.17 
II. MINNESOTA RXCONNECT 
On January 30, 2004, Minnesota RxConnect (RxConnect) was 
launched, making Minnesota the first state in the nation to 
establish a website to empower its citizens to purchase prescription 
medicines from Canada.18  Consumer savings and safety were the 
driving purposes for establishing RxConnect.  Health and safety are 
not served by Minnesotans foregoing needed prescription 
medicines because they are too expensive.  For more than a 
decade, many Minnesotans have been physically crossing the 
border into Canada to purchase needed prescription medicines, 
often at the encouragement of elected officials.19  The growth of 
Internet and mail-order pharmacies has increased Minnesotans’ 
access to prescription medicines from other countries.  Various 
estimates place the total sales of Canadian prescription medicines 
 
 14. Id. 
 15. Id. 
 16. Tim Pawlenty, Governor of Minnesota, Testimony to the Congressional 
Prescription Drug Access Coalition hearing in Boston, MA (Oct. 28, 2003) 
(transcript available at http://www.governor.state.mn.us/Tpaw_View_DF_ 
Article.asp?artid=654). 
 17. Id. 
 18. Press Release, Tim Pawlenty, Governor of Minnesota, Governor Pawlenty 
Unveils First-In-The-Nation Effort to Facilitate Purchase of Prescription Drugs 
from Canada (Jan. 30, 2004) (on file with author). 
 19. Press Release, Mark Dayton, United States Senator, Dayton Uses First 
Senate Speech to Press Congress and President To Make Prescription Drugs More 
Affordable for Seniors (Feb. 26, 2001), available at http://www.dayton.senate.gov/ 
news/ details.cfm?id=229450&&. 
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to the United States in a range between $600 million and $1 billion 
a year.20  RxConnect recognizes this reality and provides 
Minnesotans with information on prescription medicines, safety, 
and selected Canadian pharmacies. 
Minnesota is not alone in its effort to provide information to 
citizens who seek information on lower cost prescription 
medicines.  Although Minnesota’s RxConnect website may have 
been the first state site to go online, other state and local 
governments have quickly followed.  Wisconsin, North Dakota, 
Rhode Island, New Hampshire, as well as county and city 
governments throughout the United States, have all initiated 
prescription medicine programs for their residents.21  In expressing 
the position of the U.S. Food and Drug Administration (FDA), FDA 
Associate Commissioner of External Relations, Peter Pitts, claimed 
that “illegal, unsafe importation presents the very real danger of 
turning the Internet into the 21st century’s virtual drug cartel.”22  
William Hubbard, the FDA Associate Commissioner for Policy and 
Planning, in a letter to Governor Pawlenty, specifically attacked 
RxConnect as “unsafe, unsound, and ill-considered.”23  The 
criticisms from the FDA and other detractors of RxConnect have 
centered on concerns about the legality of the website, the safety of 
the prescription medicines and whether there are actual cost 
savings to consumers. 
III. RXCONNECT INFORMS AND PROTECTS MINNESOTA CITIZENS AND 
DOES NOT VIOLATE FEDERAL LAW 
States play a critical role in our system of government and have 
traditionally served as the nation’s laboratory for innovative 
programs that provide for the protection and general welfare of 
their citizens.  Although the federal government has authority, 
within the limitations of the Constitution, to pass laws to govern the 
country, in areas where Congress has not acted to require or 
 
 20. Christopher Rowland, Canada Threatens to Halt Shipments of Drugs to US, 
BOSTON GLOBE, Nov. 11, 2004, (located at Boston Globe Archives, 2004-11-11). 
 21. Irakli Khodeli, Prescription Drug Importation Gains Momentum, STATE NEWS, 
August 2004, at 14, 15. 
 22. Peter J. Pitts, Associate Commissioner for External Relations, FDA, 
Remarks at the NCSL Health Leaders Seminar (Dec. 10, 2003), available at 
http://www.ncsl.org/programs/health/pitts.htm. 
 23. Letter from William K. Hubbard, Associate Commissioner for Policy and 
Planning, FDA, to Tim Pawlenty, Governor, Minnesota (Feb. 23, 2004), available at 
http://www.fda.gov/oc/opacom/hottopics/importdrugs/pawlenty022304.html. 
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prohibit an action, the states generally remain free to exercise their 
authority.24 
Governor Pawlenty’s prescription medicine website reflects an 
appropriate exercise of authority by the State of Minnesota.  
RxConnect provides information to Minnesotans so that they can 
make informed decisions in relation to their purchase of 
prescription medicines.25  The state’s efforts to inspect participating 
Canadian pharmacies fits within the state’s general role of actions 
to inform the public about recommended safety measures for 
pharmacies and a comparison to the measures used by pharmacies 
licensed by the state.  The information available on the RxConnect 
website enhances the potential safety for citizens who choose to 
purchase lower cost prescription medicines from Canada.26 
A. RxConnect Is Consistent with Federal Law 
Although the FDA was quick to criticize and threaten 
Governor Pawlenty and other state and local officials who created 
programs to inform their citizens about the significant cost savings 
on prescription medicines available in the Canadian market,27 
 
 24. See U.S. CONST. amend. X (“The powers not delegated to the United 
States by the Constitution, nor prohibited by it to the States, are reserved to the 
States respectively, or to the people”). 
 25. RxConnect provides information about safe purchasing and use of 
prescription drugs, cost-saving tips and links to assistance programs, instructions 
for ordering medicine from participating pharmacies, and information on the 
participating pharmacies and the selection process.  Minnesota RxConnect, How to 
Use This Site, at http://www.state.mn.us/cgi-bin/portal/mn/jsp/content.d 
o?contentid=536901930&contenttype=EDITORIAL&hpage=true&agency=Rx (last 
visited Jan. 28, 2005). 
 26. For example, RxConnect provides advice on how to properly use and 
store prescription drugs and advice about shopping for drugs on the internet.  
Minnesota RxConnect, Safety First, at http://www.state.mn.us/cgi-
bin/portal/mn/jsp/content.do?id=-536885275&agency=Rx (last visited Jan. 28, 
2005). 
 27. See FDA, Importing Prescription Drugs, Letters to State and Local Officials, 
available at http://www.fda.gov/oc/opacom/hottopics/importdrugs/ (last visited 
Jan. 27, 2005).  Recipients of the letters include: Minnesota Governor Tim 
Pawlenty, Wisconsin Governor Jim Doyle, Illinois Governor Rod Blagojevich, 
Rhode Island Governor Donald Carcieri, New Hampshire Governor Craig Benson, 
Washington D.C. Mayor Anthony A. Williams, and Caldwell County North 
Carolina administrator Bobby White.  Springfield, Massachusetts and Birmingham, 
Alabama have undertaken importation programs for their residents.  The State of 
Vermont is also currently suing the Secretary of the federal Department of Health 
and Human Services in relation to the FDA’s refusal to allow Vermont to initiate a 
pilot importation program.  In Minnesota, Governor Pawlenty and Human 
Services Commissioner Kevin Goodno have taken issue with the accuracy of 
6
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Minnesota’s prescription medicine program is consistent with 
federal law.  RxConnect provides information to consumers so that 
the consumer can make their own informed choices regarding 
their health care.  Nothing in federal law prohibits states, 
individuals, or any other entity from providing information or even 
from advocating the importation of prescription medicines.  
Moreover, RxConnect reflects Minnesota’s exercise of its 
traditional power as a state to inform and protect its citizens.28  
These rights have not been preempted by federal law.29  As a result, 
Minnesota’s program falls squarely within the protection of the 
First Amendment and the protection of state authority granted by 
the Tenth Amendment of the United States Constitution.30 
B. Importation Under the FDCA 
The Federal Food, Drug, and Cosmetic Act31 (FDCA) governs 
importation of prescription medicines in the United States.  As to 
importation of pharmaceutical products from foreign countries, 
the FDCA distinguishes between importation of pharmaceutical 
products that were manufactured in the United States and 
 
assertions made by FDA officials and have provided specific responses to the 
assertions made in the FDA letters.  See Letter from Kevin Goodno, Commissioner, 
Minnesota Department of Human Services, to William K. Hubbard, Associate 
Commissioner for Policy and Planning, FDA, (Mar. 9, 2004) (on file with author). 
 28. States traditionally have the power to enact legislation to protect the 
health and safety of their citizens.  Medtronic, Inc. v. Lohr, 116 S. Ct. 2240, 2245 
(1996) (quoting Hillsborough County v. Automated Med. Labs., Inc., 471 U.S. 
707, 719, 105 S. Ct. 2371, 2378, 85 L. Ed.2d 714 (1985), Metro. Life Ins. Co. v. 
Massachusetts, 471 U.S. 724, 756, 105 S. Ct. 2380, 2398 (1985)).  These traditional 
powers are called police powers.  “[T]he police power of a state embraces 
regulations designed to promote the public convenience or the general 
prosperity, as well as regulations designed to promote the public health, the public 
morals, or the public safety.”  Chicago, B. & Q. Ry. Co. v. Illinois, 26 S. Ct. 341, 349 
(1906). 
 29. Federal preemption requires that state law must give way when it conflicts 
with or frustrates federal law.  See U.S. CONST. art. VI cl. 2.  “State law is preempted 
when Congress expressly prohibits state regulation, when Congress implicitly 
leaves no room for state involvement by pervasively occupying a field of regulation, 
and when state law directly conflicts with federal law.”  Chapman v. Lab One, 390 
F.3d 620, 624 (8th Cir. 2004); see 16A AM. JUR. 2D Constitutional Law § 241. 
 30. See U.S. CONST. amend. I (“Congress shall make no law. . . abridging the 
freedom of speech”); U.S. CONST. amend. X (“[t]he powers not delegated to the 
United States by the Constitution, nor prohibited by it to the States, are reserved 
to the States”). 
 31. 21 U.S.C. § 301 (2000). 
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products that were manufactured in other countries.32  The FDCA 
prohibits any importation into the United States of a prescription 
medicine that was originally manufactured in the United States.33  
Prescription medicines that are initially manufactured within the 
United States and later exported may be brought back into the 
United States only by the product’s manufacturer.34  Thus, once 
prescription medicines manufactured within the United States 
leave the country, nobody except the manufacturer can import the 
prescription medicine back into the country and into the stream of 
commerce. 
Prescription medicines manufactured in countries other than 
the United States can be legally imported into the United States if 
the medicines comply with the FDCA.  It is not a violation of the 
Act to import FDA-approved prescription medicines that were 
manufactured outside of the United States if the product is 
properly labeled in accordance with the FDCA and distributed with 
a valid prescription.35  The FDA has taken the position that almost 
all importation of prescription medicines manufactured outside of 
the United States will violate the FDCA.36  The FDA asserts that in 
order to be FDA-approved the imported medicines must comply 
with all of the product-specific, manufacturer-specific, process-
specific, and labeling-specific requirements established for the 
manufacturer’s FDA application and approved by the FDA in 
accordance with federal regulations.37  Under the FDA’s analysis, 
any slight variation or technical deviation in the content or 
packaging from the U.S. equivalent makes the product an 
“unapproved” product.38 
 
 32. See, e.g., 21 U.S.C. at § 381(d)(1). 
 33. Id. 
 34. Id. 
 35. See 21 U.S.C. §§ 355 (unapproved drugs), 352 (labeling requirements), 
and 353(b)(1) (prescription drugs). 
 36. Letter from William K. Hubbard, Associate Commissioner for Policy and 
Planning, FDA to Robert P. Lombardi, Esq., the Kullman firm (Feb. 12, 2003), 
available at http://www.fda.gov/ora/import/kullman.htm. 
 37. Id. (citing 21 C.F.R. § 314.50 (2004)). 
 38. The significance underlying the differences between the importation 
provisions is highlighted by the reality of the global manufacturing process for 
prescription medicines.  Currently, prescription medicines available in the United 
States are manufactured around the globe.  Lipitor, a popular cholesterol-
lowering medicine manufactured by Pfizer, Inc., is manufactured in Ireland.  See 
Lipitor Product Information, available at http://www.lipitor.com/cwp/app 
manager/lipitor/lipitorDesktop?_nfpb=true&_pageLabel=prescribingInformation 
(last visited Feb. 5, 2005). 
8
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Importation of prescription medicines in violation of the 
FDCA, or the “causing thereof,” is prohibited by the Act.39  A 
violation of the Act, if enforced, can result in an administrative 
warning, civil legal action for injunctive relief, seizure of product, 
and in some cases, criminal prosecution.40 
The provisions of the FDCA prohibiting certain importation of 
prescription medicines may give way to broader legalization of 
importation programs.  Congress has expressly recognized the 
need to explore the safe importation of prescription medicines.  In 
2000, Congress made specific factual findings regarding access to 
affordable prescription medicines in alternative markets: 
(1) The cost of prescription drugs for Americans 
continues to rise at an alarming rate. 
(2) Millions of Americans, including Medicare 
beneficiaries on fixed incomes, face a daily choice 
between purchasing life-sustaining prescription drugs, or 
paying for other  necessities, such as food and housing. 
(3) Many life-saving prescription drugs are available in 
countries other than the United States at substantially 
lower prices, even though such drugs were developed and 
are approved for use by patients in the United States. 
(4) Many Americans travel to other countries to purchase 
prescription drugs because the medicines that they need 
are unaffordable in the United States. 
(5)  Americans should be able to purchase medicines at 
prices that are comparable to prices for such medicines in 
other countries, but efforts to enable such purchases 
should not endanger the gold standard for safety and 
effectiveness that has been established and maintained in 
the United States.41 
These congressional findings recognize the plight of millions 
of Americans: they are struggling to afford costly prescription 
medicine, they are already crossing borders to obtain their 
medicines, and the need for appropriate safety protections in 
relation to accessing affordable prescription medicines available in 
other markets. 
In 2000, Congress amended the FDCA to require the Secretary 
 
 39. See 21 U.S.C. § 331(a), (d), (t) (2000). 
 40. See 21 U.S.C. §§ 331-34, 336-37 (2000). 
 41. Medicine Equity and Drug Safety Act of 2000, H.R. 4461, 106th Cong. § 
745(b) (2000); Pub. L. No. 106-387, § 745(b), 114 Stat. 1549 (2000). 
9
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of Health and Human Services, in consultation with the United 
States Trade Representative, to promulgate regulations permitting 
pharmacists and wholesalers to import pharmaceutical products 
covered by the FDCA.42  Under these new provisions, the Secretary 
of Health and Human Services was required to develop safeguards 
to ensure that imported products comply with key provisions of the 
FDCA regarding safety and efficacy, and develop safeguards that 
generally provide for the protection of the public.43  However, the 
2000 amendments contained a provision that significantly 
weakened the directive to the Secretary to create regulations: 
“[t]his section shall become effective only if the Secretary 
demonstrates to the Congress that the implementation of this 
section will (1) pose no additional risk to the public’s health and 
safety; and (2) result in a significant reduction in the cost of 
covered products to the American consumer.”44  Based on this 
provision, the Secretary of Health and Human Services under both 
the Clinton and Bush administrations has declined to make the 
certification. 
In 2003, Congress significantly amended this new provision.  
The amendments specifically require the development of 
regulations that permit the importation of prescription medicines 
from Canada by pharmacists and wholesalers.45  Significantly, the 
2003 amendments for the first time provide directives to the 
Secretary of Health and Human Services in relation to importation 
of prescription medicines by individuals for personal use: 
Declarations. Congress declares that in the enforcement 
against individuals of the prohibition of importation of 
prescription drugs and devices, the Secretary should 
(A)  focus enforcement on cases in which the 
importation by an individual poses a significant threat 
to public health; and 
(B)  exercise discretion to permit individuals to make 
such importations in circumstances in which 
(i)  the importation is clearly for personal use; 
and 
(ii)  the prescription drug or device imported 
 
 42. 21 U.S.C. § 384(a) (2000). 
 43. Id. § 384(b). 
 44. Id. § 384(l). 
 45. Id. § 384(b). 
10
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does not appear to present an unreasonable risk 
to the individual.46 
The Secretary can address personal use enforcement by either 
providing for case-by-case waivers to individuals, or by regulation 
on specific prescription medicines or a class of medicines.47  As to 
prescription medicines imported from Canada, the amendment 
provides that 
the Secretary shall by regulation grant individuals a waiver 
to permit individuals to import into the United States a 
prescription drug that (A) is imported from a licensed 
pharmacy for personal use by an individual, not for resale, 
in quantities that do not exceed a 90-day supply; (B) is 
accompanied by a copy of a valid prescription; (C) is 
imported from Canada, from a seller registered with the 
Secretary; (D) is a prescription drug approved by the 
Secretary . . . ; (E) is in the form of a final finished dosage 
that was manufactured in an establishment registered 
under section 360.48 
The Secretary can also impose other conditions deemed necessary 
to ensure public safety.49 
The 2003 amendments continue the condition that the 
provisions become effective only if the Secretary certifies that the 
provision will “pose no additional risk of harm.”50  Congress 
suggested the Secretary of Health and Human Services should 
conduct a study on the importation of drugs under the 2003 
amendments to the FDCA.51  If the Secretary submits a certification 
report on the study to Congress within twelve to eighteen months 
from the date of enactment stating that the benefits do not 
outweigh the detrimental effects of the amendments, they will 
cease to have effect.52  In December of 2004, the Secretary issued 
his Report on Prescription Drug Importation to Congress finding 
that the benefits of drug importation did not outweigh the risks of 
potential harm to the American public.53  At this point, unless 
Congress acts to establish a safe importation program, further 
 
 46. Id. § 384(j)(1)(1). 
 47. Id. § 384(j)(2). 
 48. Id. § 384(j)(3). 
 49. Id. § 384(j)(3)(F). 
 50. Id. § 384(l). 
 51. Id. § 384(l)(2)(A). 
 52. Id. 
 53. Report on Prescription Drug Importation, HHS Task Force on Drug 
Importation, United States Department of Health and Human Services, December 2004. 
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action by the FDA to establish such program appears unlikely.54 
C. FDA’s Current Personal Use Policy 
Notwithstanding the 2003 amendment to the FDCA, relating 
to the possible development of regulations or waiver procedures 
for the importation of prescription medicines for personal use, the 
FDA has had a longstanding practice of not enforcing the FDCA’s 
importation prohibitions against individuals who are importing 
small amounts of prescription medicines for personal use.  The 
FDA has expressly recognized in its Regulatory Procedures Manual 
an exemption on enforcement for personal importations.55  The 
general guidance in the Regulatory Procedures Manual56 provides, 
in relevant part: 
FDA personnel may use their discretion to allow entry of 
shipments of violative FDA regulated products when the 
quantity and purpose are clearly for personal use, and the 
product does not present an unreasonable risk to the 
user.  Even though all products that appear to be in 
violation of statutes administered by FDA are subject to 
refusal, FDA personnel may use their discretion to 
examine the background, risk, and purpose of the 
product before making a final decision.  Although FDA 
may use discretion to allow admission of certain violative 
items, this should not be interpreted as a license to 
individuals to bring in such shipments. . . . Commercial 
and promotional shipments are not subject to this 
guidance.57 
The Regulatory Procedures Manual provides that FDA 
personnel should not examine personal baggage (a function to be 
 
 54. There continues to be interest in Congress for establishing a prescription 
medicine importation program.  On February 16, 2005, Governor Pawlenty testified 
about Minnesota’s efforts in relation to lowering the costs of prescription medicines 
before the Senate Committee on Health, Education, Labor, and Pensions.  Governor 
Pawlenty’s testimony is available at http://www.governor.state.mn.us/ 
tpaw_view_article.asp?artid=1260. 
 55. See OFFICE OF REGULATORY AFFAIRS, U.S. FOOD AND DRUG ADMIN., 
REGULATORY PROCEDURES MANUAL: Ch. 9 IMPORT OPERATIONS/ACTIONS (2004 ed.), 
available at http://www.fda.gov/ora/compliance_ref/rpm_new2/ch9/ 
default.htm. 
 56. See id.  The personal importation provisions are contained in the 
Regulatory Procedures Manual (RPM), Chapter 9, in the subchapter on Coverage 
of Personal Importations.  As of January 2005, Chapter 9 of the RPM, which 
addresses import operations/actions, was being revised. 
 57. Id. 
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left to the U.S. Customs Service) and that the guidance in relation 
to personal importations is intended to apply both to personal mail 
shipments and personal baggage.58 
As a greater number of Americans have looked to Canada for 
relief from high prescription medicine prices and the importation 
issues have grown in national prominence, the FDA has issued 
several informational letters asserting a narrow application of the 
personal-use policy.59  The FDA has publicly asserted that the 
discretion provided by the personal-use policy is intended to apply 
only to allow for “medical treatments sought by individuals that are 
not otherwise available in the United States” and not in scenarios 
where the FDA-approved medicines are available more cheaply in 
the foreign country.60 
The guidance identifies circumstances in which the FDA may 
consider exercising enforcement discretion and refrain from taking 
legal action against illegally imported drugs. Those circumstances 
are as follows: 
1) the intended use [of the drug] is unapproved and for a 
serious condition for which effective treatment may not be 
available domestically either through commercial or 
clinical means; 
2) there is no known commercialization or promotion to 
persons residing in the U.S. by those involved in the 
distribution of the product at issue; 
3) the product is considered not to represent an 
unreasonable risk; and 
4) the individual seeking to import the product affirms in 
writing that it is for the patient’s own use (generally not 
more than a 3 month supply) and provides the name and 
address of the doctor licensed in the U.S. responsible for 
his or her treatment with the product, or provides 
evidence that the product is for the continuation of a 
treatment begun in a foreign country.61 
 
 58. Id. 
 59. See, e.g., OFFICE OF REGULATORY AFFAIRS, U.S. FOOD AND DRUG ADMIN., 
INFORMATION ON IMPORTATION OF DRUGS PREPARED BY THE DIVISION OF IMPORT 
OPERATIONS AND POLICY, FDA (Apr. 3, 1998), available at 
http://www.fda.gov/ora/import/pipinfo.htm. 
 60. Id. 
 61. OFFICE OF REGULATORY AFFAIRS, U.S. FOOD AND DRUG ADMIN., IMPORTATION 
OF PRESCRIPTION MEDICINES/DRUGS, TRAVEL ALERT, available at 
http://www.fda.gov/ora/import/traveler_alert.htm (last visited Feb. 5, 2005) 
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Although the FDA has recently gone out of its way to 
emphasize that it believes it has a right to take enforcement action 
against individuals importing prescription medicines available in 
the United States for their personal use, the FDA has generally not 
pursued such action against individuals.62  Recently, however, the 
FDA took action to seize a number of personal mail shipments of 
prescription medicines that had been ordered by seniors in 
Minnesota, Wisconsin, and other states through a Canadian 
Internet pharmacy.63  When the FDA’s action resulted in angry 
outcries from senior citizen advocacy groups and federal senators 
from Minnesota and Wisconsin, the FDA released the shipments to 
the individuals.64 
D. FDA Enforcement: The Rx Depot, Inc. Case 
Although legal action against individuals has not been pursued 
by the federal government, the FDA has pursued legal action 
against a private company in relation to importation of prescription 
medicines.  In United States v. Rx Depot, Inc., the United States 
brought a legal action against Rx Depot, Inc., affiliated companies, 
and individual officers of Rx Depot to enjoin alleged violations of 
the FDCA.65  Rx Depot sold U.S. customers prescription medicines 
ordered from a Canadian pharmacy.66  The customers brought 
their prescriptions, required medical forms, and payment 
information directly to Rx Depot, which transmitted the 
information to a participating Canadian pharmacy.67  Rx Depot 
received a direct commission on each sale filled by the Canadian 
pharmacy.68  The court found that Rx Depot essentially worked as a 
commissioned sales force for the Canadian pharmacy.69 
In issuing the preliminary injunction,70 the court found that 
 
(emphasis in original). 
 62. See, e.g., Letter from William K. Hubbard, FDA Associate Commissioner 
for Policy and Planning, to Robert P. Lombardi, Esq., The Kullman Firm (Feb. 12, 
2003), available at http://www.fda.gov/ora/import/kullman.htm. 
 63. Julie Appleby, Drugs from Canada Seized, USA TODAY, Sept. 17, 2004, at 5B. 
 64. See Drug Importation; Wisconsin Senators Ask FDA Why it Intercepted Drugs from 
Canada, HEALTH & MED. WK., Oct. 4, 2004, at 455. 
 65. 290 F. Supp. 2d 1238 (N.D. Okla. 2003). 
 66. Id. at 1240-41. 
 67. Id. 
 68. Id. at 1241. 
 69. Id. 
 70. Id. at 1250.  Rx Depot’s motion to stay the preliminary injunction 
imposed by the court was denied in United States v. Rx Depot, Inc., 297 F. Supp. 2d 
14
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the United States was likely to prevail on its claims that Rx Depot’s 
role in the transaction “caused” the importation of prescription 
medicines originally manufactured in the United States, as well as 
the importation of new unapproved medicines manufactured in 
foreign countries in violation of the FDCA.71 
E. Minnesota’s RxConnect Program Does Not Violate the FDCA 
The FDA has been quick to criticize state and local officials 
who take action to inform their citizens about the availability and 
affordability of prescription medicines from Canada.72  
Nevertheless, to date, the FDA has not attempted to enjoin any of 
the state or local government entities that have set up programs to 
inform citizens regarding Canadian prescription medicines.   
Even if challenged by the FDA, RxConnect does not violate the 
FDCA.  RxConnect is specifically set up to provide information to 
Minnesotans and through that information help protect the safety 
of Minnesotans who choose to pursue a purchase of prescription 
medicines from Canada.  Although an individual can obtain 
information and download order forms from the website, the state 
of Minnesota does not participate in any manner in the decision 
made by the consumer or in the transaction conducted with the 
Canadian pharmacy.  The state also does not receive any type of 
compensation or benefit from the pharmacy or the consumer.   
Instead, the RxConnect website merely provides a comparison 
of prescription medicine costs in the United States with costs in 
Canada, information on the possibility of cheaper generic 
medicines in the United States, and safety tips regarding 
prescription medicines.73  The information provided on the website 
makes it clear that the purpose of the program is to inform 
Minnesotans, and “to provide Minnesotans information on issues 
related to prescription medicine, safety and cost-saving tips, and 
programs to help low-income Minnesotans pay for prescription 
medications.”74  The RxConnect website also provides Minnesotans 
 
1306 (N.D. Okla. 2003). 
 71. Rx Depot, 290 F. Supp. 2d at 1247. 
 72. See, e.g., Letter from William K. Hubbard, Associate Commissioner for 
Policy and Planning, FDA, to Tim Pawlenty, Governor, State of Minnesota (Feb. 
23, 2004) (on file with author). 
 73. See Minnesota RxConnect Online, at http://www.state.mn.us/cgi-
bin/portal/mn/jsp/home.do?agency=Rx (last modified Jan. 11, 2005). 
 74. See Minnesota RxConnect Online, at http://www.state.mn.us/cgi-
bin/portal/mn/jsp/content.do?id=-536885395&agency=Rx (last modified Jan. 11, 
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with information about, and the identity of, pharmacies that have 
been visited by Minnesota officials and information regarding the 
safety standards used by the four pharmacies featured on the 
website.75 
Individual consumers ultimately decide whether it is in their 
interests to purchase their prescription medicines from Canada.  
Given RxConnect’s public safety and information functions, there 
is no legal basis to conclude Minnesota has violated or “caused” a 
violation of the FDCA.76  The state is no more involved in the 
transaction than any other public interest group or media outlet 
that provides information to the public concerning prescription 
medicines.   
Moreover, a conclusion that RxConnect violated the FDCA 
would implicate important constitutional mandates.  First, the state, 
acting through its public officials, has the right to free speech—
especially where such speech bears directly on matters of public 
policy and the safety of citizens.77  State officials could obviously 
share any of the information contained on RxConnect orally, which 
includes providing information about the pharmacies that are 
willing to take orders from Minnesotans.  The fact that a website is 
used as the medium for communication rather than oral 
communication does not change the nature of the speech. 
The key feature of RxConnect is the state’s role in visiting 
Canadian pharmacies, reviewing their safety protocols in 
comparison with state pharmacy standards and discussing 
procedures to provide enhanced safety in relation to the 
importation of prescription medicines.78  It is well documented that 
before Minnesota undertook these functions, many Minnesotans 
were already crossing the border, either physically or electronically, 
to purchase necessary prescription medicines.  The need for 
additional information and protection was clear.  By providing 
RxConnect, Minnesota helps to ensure that its citizens who chose 
to purchase medicines from Canada, have a resource available for 
making an informed decision. 
 
2005). 
 75. Id. 
 76. See 21 U.S.C. § 301 (2000). 
 77. See U.S. CONST. amend. I. 
 78. See Minnesota RxConnect Online, at http://www.state.mn.us/cgi-
bin/portal/mn/jsp/content.do?contentid=536902091&contenttype=EDITORIAL
&subchannel=null&sc3=null&sc2=null&id=-536885147&agency=Rx (detailing 
pharmacy screening criteria) (last modified Jan. 11, 2005). 
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Finally, even assuming that the applicable provisions of the 
FDCA reflect Congress’ valid exercise of authority under the 
Commerce Clause,79 the scope of the FDCA must be interpreted in 
light of the Tenth Amendment’s reservation of authority to the 
states.80  Although Congress has the authority to regulate foreign 
trade, RxConnect does not in any manner negate Congress’ 
authority to regulate trade, the regulatory structure established by 
the FDCA, or the FDA’s authority to enforce the FDCA. 
Nothing in the FDCA prohibits states from traveling to foreign 
countries to review the safety procedures used by foreign 
pharmacies.81  Similarly, there is no prohibition against states, or 
anyone else, providing information to the public as to the safety 
standards used by foreign pharmacies or negotiating with such 
pharmacies for safer, more effective practices.82  Without such a 
prohibition under the Constitution or the FDCA, such power is 
reserved to the states and to the citizens.83  That the information 
and efforts of the states or citizens results in more individuals 
choosing to import prescription medicines from other countries in 
a manner that the FDA believes violates the FDCA, and which the 
FDA may or may not choose to enforce against the individual, does 
not alter the result. 
IV. RXCONNECT ENHANCES THE SAFETY OF PRESCRIPTION 
MEDICINES ORDERED FROM CANADA 
The FDA’s safety concerns revolve around the operation of the 
mail-order pharmacies and the safety of the prescription 
medicines.84  The safety issues related to the pharmacies range from 
allegations of poor operating practices to outright criminal 
activity.85  The FDA has been at the forefront of the warnings about 
 
 79. See U.S. CONST. art. I, § 8. 
 80. See U.S. CONST. amend. X. 
 81. See 21 U.S.C. § 301 (2000). 
 82. See id. 
 83. See U.S. CONST. amend. X (“The powers not delegated to the United 
States by the Constitution, nor prohibited by it to the States, are reserved to the 
States respectively, or to the People.”). 
 84. Letter from William K. Hubbard, Associate Commissioner for Policy and 
Planning, FDA, to Tim Pawlenty, Governor, State of Minnesota (Feb. 23, 2004) 
(on file with author). 
 85. See id.; see also Canadian Prescription Drug Re-importation: Is There a Safety 
Issue?: Hearing Before the House Committee on Government Reform, Subcommittee on 
Human Rights and Wellness, 108th Cong. (June 12, 2003) (statement of William K. 
Hubbard, Associate Commissioner for Policy and Planning, FDA), available at 
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the safety of mail-order pharmacies.  William Hubbard has argued 
that the FDA does not “know of people getting sick or dying yet, 
but people are at risk.”86  In his testimony to Congress, Hubbard 
outlined his agency’s specific concerns regarding the safety of 
prescription medicines ordered from Canada, primarily that the 
product could be expired, contaminated, counterfeit, wrong, or 
sub-potent.87  In addition, the product could be of an incorrect 
dosage, lack an English language label, lack proper directions, or 
have experienced degradation due to improper handling.88  
Although warning of the dangers of Canadian mail-order 
prescription medicines, Pitts has admitted that “Canadian drugs are 
safe.  If you walk into a pharmacy in Windsor, Ontario, and have a 
prescription filled by a real pharmacist—the drugs you receive will 
be both safe and effective.”89   
RxConnect offers Minnesotans a safe alternative to border 
crossings and unknown, unregulated international websites.  The 
guidelines established for RxConnect and the process followed to 
select Canadian pharmacies and to limit the prescription medicines 
listed on RxConnect were rigorous and established with a focus on 
making certain that consumers are receiving prescription 
medicines approved for Canada from a real pharmacist—in other 
words, prescription medicines that are safe and effective. In 
launching RxConnect the single most important factor in 
providing for consumer safety and addressing the concerns of the 
FDA was choosing the participating Canadian pharmacies.90 
A. Pharmacies Listed on RxConnect are Inspected and Licensed 
In November of 2003, the Minnesota Department of Human 
Services (DHS) developed a request for responses: a document that 
 
http://reform.house.gov/UploadedFiles/Hubbard%20Testimony%206-12-03.pdf  
[hereinafter Re-importation Hearing]; Peter J. Pitts, Associate Commissioner for 
External Relations, FDA, Prescription Drugs: Latest News, Latest Views, Remarks at the 
National Conference of State Legislatures, Health Leaders Seminar (Dec. 10, 
2003), available at http://www.ncsl.org/programs/health/pitts.htm [hereinafter 
Pitts]. 
 86. Warren Wolfe, Modest Start for State Drug Sales, STAR TRIBUNE, 
(Minneapolis, St. Paul), July 21, 2004 at A1, available at 2004 WL 83076194 at *1. 
 87. Re-importation Hearing, supra note 85.   
 88. Id. 
 89. Pitts, supra note 85.   
 90. See Letter from Kevin Goodno, Commissioner, Minnesota Department of 
Human Services, to William K. Hubbard, Associate Commissioner for Policy and 
Planning, FDA (Mar. 9, 2004) (on file with author). 
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requested responses to a series of questions from identified 
Canadian mail-order pharmacies.  The minimum requirements 
were that the responder: was licensed to do business as a pharmacy 
in the Canadian province in which it was located; had been 
accredited or was eligible for accreditation by the Internet and 
Mail-order Pharmacy Accreditation Commission and/or be a 
member of the Canadian International Pharmacy Association; and 
that all health care professionals employed by or under contract 
with the responder, including pharmacists and physicians, have the 
appropriate professional license.91 
The pharmacies were also asked to present detailed 
information concerning their business experience, staff, facilities, 
prescription medicine supply sources, prescription-filling process, 
and other policies and procedures.92  DHS received twenty-seven 
responses that were ranked based on the evaluation of their 
responses.93  In addition, the following were considered: 
1.  One responder was excluded from further 
consideration because it was not a pharmacy but operated 
a website affiliated with a pharmacy. 
2.  Some responders were excluded because they did not 
operate at one location.  Instead, a prescription ordered 
from their websites might be routed to one of several or 
even many pharmacies for actual filling. 
3.  Some responders were excluded because of their 
relatively remote locations.  For example, one pharmacy is 
located approximately two hours away from Winnipeg.  
Minnesota Board of Pharmacy Surveyors felt that a 
minimum of three or four hours should be spent at each 
facility.  Therefore, driving to and from the more remote 
locations was not an option.94 
Nine pharmacies were chosen for site visits.95  The DHS 
Pharmacy Program Manager and two Board of Pharmacy surveyors, 
 
 91. Request for Responses: Canadian Pharmacies, Minnesota Department of 
Human Services, Health Care Administration (Dec. 2003) (on file with author). 
 92. Id. 
 93. Undated internal memorandum from Cody Wiberg, Pharmacy Program 
Manager, Minnesota Department of Human Services, to Kevin Goodno, 
Commissioner, Minnesota Department of Human Services (on file with author). 
 94. Id. 
 95. Report on the survey of Canadian pharmacies, from Cody Wiberg, 
Pharmacy Program Manager, Minnesota Department of Human Services, to Kevin 
Goodno, Commissioner, Minnesota Department of Human Services (June 21, 
2004) (on file with author). 
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all Minnesota licensed pharmacists, visited eight of the nine 
pharmacies initially selected for further review.96  The ninth 
pharmacy selected for additional review was unable to be reached 
for a site visit.  The team considered the following when visiting the 
facilities:  
1.  Quality of the facilities.  The physical condition of the 
facilities was considered, including the “[l]ighting, [the] 
presence of a thermometer in medication refrigerators, 
adequate space for the number of staff on duty, general 
upkeep of facilities” and additional factors.97 
2.  Operational procedures.  The workflow, presence of 
appropriate safety checks and adequate monitoring of 
non-professional staff by pharmacists were reviewed.98 
3.  Source of prescription medicine.  Prescription 
medicine packages were randomly checked for presence 
of labeling that indicated the products had been approved 
for use in Canada.99 
4.  Answers to questions.  Questions were posed to staff 
about: “shipping and returns policies, procedures for 
counseling patients on proper use of medications, the 
role of Canadian physicians in the process, adequacy of 
prescription [medicine] supply, source of prescription 
medicines dispensed and other issues.”100 
5.  Evidence of Licensure.  Evidence that the pharmacy 
and pharmacists were appropriately licensed by the 
province in which the pharmacy is located.101 
Based on the recommendations of the inspection team, two 
pharmacies were initially selected to participate in the Minnesota 
program.102  Both of these pharmacies appeared to operate in an 
efficient, safe, and professional manner.103  Two additional 
pharmacies were added to the program in June 2004 after a similar 
selection process was followed. 
 
 96. Id. 
 97. Undated internal memorandum from Cody Wiberg, Pharmacy Program 
Manager, Minnesota Department of Human Services, to Kevin Goodno, 
Commissioner, Minnesota Department of Human Services (on file with author). 
 98. Id. 
 99. Id. 
 100. Id. 
 101. Id. 
 102. Id. 
 103. Id. 
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To support the FDA position that the Canadian mail-order 
pharmacies themselves were unsafe, Hubbard cited Minnesota’s 
report on its site inspections of Canadian pharmacies.104  Hubbard 
noted that the report listed “dozens of safety problems” with the 
pharmacies inspected.105  However, Hubbard’s characterization that 
the report proved that ordering prescription medicines from 
Canada is unsafe was inaccurate.106  In a letter to Hubbard, 
Minnesota DHS Commissioner Kevin Goodno responded to 
Hubbard’s contentions by noting that Hubbard had made “at least 
eight clear misstatements of fact regarding [the Minnesota] site 
visit findings.”107  Each misstatement exaggerated either the 
breadth or the severity of the deficiencies found by [the inspectors] 
in [their] site inspections of the Canadian pharmacies.”108  Of the 
specific findings from these visits, most did not relate to the two 
pharmacies chosen for inclusion in the program.109  Further, 
“[s]ome of the findings that were characterized as dangerous 
practices in [Hubbard’s] letter [are] commonly [cited] during 
inspections of local, U.S. pharmacies.”110  Most of the safety 
problems identified in the Minnesota report “would normally be 
handled with a finding and order to correct—not by shutting down 
the pharmacy.”111 
Of the two initial pharmacies selected, there were items 
identified by the inspectors for improvement.  For the first 
pharmacy selected, two issues were identified: (1) inadequate 
lighting and (2) the failure of one of the pharmacists to record the 
drug’s Drug Identification Number (DIN).112  Although the lighting 
was adequate in most work areas it did not meet Minnesota 
standards.  However, “new lighting was being installed the day the 
surveyors were visiting.”113  Also, the surveyors recommended to the 
 
 104. Letter from William K. Hubbard, Associate Commissioner for Policy and 
Planning, FDA, to Tim Pawlenty, Governor, State of Minnesota (Feb. 23, 2004) 
(on file with author). 
 105. Id. 
 106. See Letter from Kevin Goodno, Commissioner, Minnesota Department of 
Human Services, to William K. Hubbard, Associate Commissioner for Policy and 
Planning, FDA (Mar. 9, 2004) (on file with author). 
 107. Id. 
 108. Id. 
 109. Id. 
 110. Id. 
 111. Id. 
 112. Id. 
 113. Id. 
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Canadian pharmacists that the DIN, Canada’s equivalent to the 
National Drug Code (NDC) used in the United States, be written 
on the paper prescription when doing the final check.114  One 
pharmacist at the pharmacy chose not to follow this procedure 
because he felt it was unnecessary; however, Minnesota pharmacists 
are not required by Minnesota law to write a drug’s NDC on a 
prescription when it is being checked.115  Accordingly, such a 
requirement would hold the Canadian pharmacists to a “higher 
standard than that for Minnesota pharmacists.”116 
The second pharmacy selected had three issues of concern 
identified.  Like the first pharmacy, its lighting did not meet 
Minnesota standards but the pharmacy “upgraded its lighting prior 
to the launch of RxConnect.”117  A follow-up inspection in July 2004 
revealed that the lighting at this pharmacy now exceeds 
Minnesota’s standard.118  The pharmacy “also had a practice of 
forwarding only the electronic health information transcribed into 
its computer system to the Canadian physician, and the surveyors 
recommended that both the original information and the 
transcribed electronic information be forwarded for review by the 
physician.”119  This policy was also subsequently changed.  Finally, at 
the request of the inspectors, the pharmacy changed its computer 
system to default to “allergies unknown” rather than “no allergies” 
when a customer did not provide allergy information.120 
All the issues of concern identified by the inspectors were 
addressed before RxConnect was launched.  The Minnesota 
inspections did reveal that significant differences do exist among 
Canadian Internet pharmacies regarding the quality of their 
respective facilities and the safety standards followed in their 
operations.  However, contrary to the representations of the FDA, 
the inspections showed that there are both high quality pharmacies 
and lower quality pharmacies operating in Canada.  These findings 
 
 114. Id. 
 115. Id. 
 116. Id. 
 117. Id. 
 118. Report on the survey of Canadian pharmacies, from Cody Wiberg, 
Pharmacy Program Manager, Minnesota Department of Human Services, to Kevin 
Goodno, Commissioner, Minnesota Department of Human Services (June 21, 
2004) (on file with author). 
 119. Letter from Kevin Goodno, Commissioner, Minnesota Department of 
Human Services, to William K. Hubbard, Associate Commissioner for Policy and 
Planning, FDA (Mar. 9, 2004) (on file with author). 
 120. Id. 
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actually support Governor Pawlenty’s contention that RxConnect is 
necessary to protect the safety of Minnesotans who choose to 
purchase prescription medicines from Canada. 
In addition to FDA concerns, the Minnesota Pharmacists 
Association raised concerns that RxConnect would affect patient 
safety because it would result in the patient receiving 
uncoordinated medical care from more than one health care 
provider.121  This not only adds inefficiency to patient care, but 
could also result in harm to the patient if prescribed therapies are 
not compatible. 
This fragmentation of therapy is a real concern not only in 
ordering prescription medicines from Canada, but in receiving 
health care services in the United States—it is not a problem 
unique to ordering prescription medicines from Canada.  To 
minimize the potential negative consequences of therapy 
fragmentation, the participating pharmacies also practice the 
following procedures: (1) The initial order placed by an American 
patient must include a valid U.S. prescription and a health profile 
of the patient; (2) The forms submitted by the patient are reviewed 
once received to make certain they are complete; (3) The 
prescription and health profile are forwarded to a Canadian doctor 
for review; (4) If the doctor agrees with the prescription, the doctor 
writes a Canadian prescription; (5) The forms and the Canadian 
prescription are then reviewed by a Canadian pharmacist who only 
fills the prescription if everything is in order.122 
In addition to meeting the selection criteria and the required 
procedures outlined above, RxConnect pharmacies agreed to the 
following: 
1.  The pharmacy and all its healthcare professionals must 
maintain licensure in good standing in the province in 
which it is located.123 
2.  The pharmacy must follow all applicable Canadian 
 
 121. Press Release, Minnesota Pharmacists Association, Minnesota Pharmacists 
Concerned about Governor Pawlenty’s Drug Importation Website (Jan. 30, 2004) 
(on file with author). 
 122. Report on the survey of Canadian pharmacies, from Cody Wiberg, 
Pharmacy Program Manager, Minnesota Department of Human Services, to Kevin 
Goodno, Commissioner, Minnesota Department of Human Services (June 21, 
2004) (on file with author). 
 123. Agreement between the Minnesota Department of Human Services and 
the pharmacies selected for inclusion in RxConnect, at 4 (on file with author). 
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laws.124 
3.  All orders received must include a prescription from a 
United States physician if the laws of Minnesota require a 
prescription.125 
4.  The pharmacy must ship no more than a ninety-day 
supply of medicine, or an amount not to exceed the 
prescribed amount for personal use to the patient.126 
5.  To the extent possible, the pharmacy must ship the 
ordered prescription medicine in unopened 
manufacturer’s containers.127 
6.  The pharmacy must not fill any order if it is indicated 
that the prescription was being filled for the first time.128 
7.  The pharmacy must provide periodic reports to DHS.129 
8.  The pharmacy must allow unannounced site visits by 
Minnesota inspectors to assure compliance with the 
program requirements.130  
9.  The pharmacy must only sell prescription medicines 
that are approved by the government of Canada for sale in 
Canada.131 
In establishing RxConnect Governor Pawlenty was not willing 
to compromise patient safety for the sake of low cost prescription 
medicines.  Accordingly, the selection process did not factor in 
potential price savings to consumers when selecting the Canadian 
pharmacies.  Through RxConnect, Minnesota consumers who wish 
to purchase prescription medicines from Canada have the added 
safety of knowing that the listed pharmacies are licensed under the 
laws of Canada and have been inspected by Minnesota state officials 
who found that they employ licensed professionals, follow good 
operating procedures, and operate from quality facilities.  In short, 
the RxConnect pharmacies are “real” pharmacies with “real” 
pharmacists filling the prescriptions with safe and effective 
prescription medicines. 
 
 124. Id. at 3. 
 125. Id. at 2. 
 126. Id. 
 127. Id. 
 128. Id. 
 129. Id. at 4. 
 130. Id. at 3. 
 131. Id. at 2. 
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B. Prescription Medicines Listed on RxConnect are Limited for Safety 
In addition to the safety of the pharmacies listed on 
RxConnect, the safety of the prescription medicines themselves was 
carefully considered in establishing RxConnect.  The United States 
General Accounting Office (GAO) investigated Internet 
pharmacies by attempting to place orders for thirteen different 
prescription medicines from sixty-eight different Internet 
pharmacies that were located in the United States, Canada, and 
other foreign countries.132 
The investigation found that all eighteen Canadian 
pharmacies required prescriptions from the patient’s physician, 
which was not true for twenty-four of the twenty-nine United States 
pharmacies and all twenty-one of the non-Canadian, foreign 
pharmacies.133  The report further concluded that of the 
prescription medicines ordered from Canada, sixteen of the 
eighteen samples were reported by the manufacturers to be 
unapproved for sale in the United States.134  “However, the samples 
were all found to be comparable in chemical composition to the 
products . . . ordered.”135  In other words, the samples ordered from 
Canada were not sub-potent, contaminated, counterfeit, the wrong 
product, or degraded, but they were largely considered 
unapproved because of labeling and packaging.136  For example, as 
mentioned earlier, a prescription medicine can be characterized as 
unapproved for sale in the United States even if the chemical 
composition has been approved for use in the United States, it was 
manufactured in an FDA approved facility, and it was packaged to 
FDA standards simply because it has a Canadian label on it that 
meets Canadian standards, but does not meet FDA standards. 
To further protect safety, not all available prescription 
medicines were included in RxConnect.  For example, of the 
thirteen different prescription medicines that the GAO attempted 
to purchase during its investigation, RxConnect excludes eight of 
 
 132. Internet Pharmacies Some Pose Safety Risks for Consumers and are Unreliable in 
Their Business Practices: Testimony before the Permanent Subcommittee on Investigations, 
Committee on Governmental Affairs, U.S. Senate (June 17, 2004),  available at 
http://www.gao.gov/new.items/d04888t.pdf (Testimony of Marcia Crosse, 
Director, Health Care—Public Health and Military Health Care Issues). 
 133. Id. at 9. 
 134. Id. at 16. 
 135. Id. 
 136. Id. 
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them for various safety reasons.137  The medications listed on 
RxConnect are primarily those meant to treat chronic conditions.138  
Some prescription medicines listed are sometimes taken for acute 
conditions, but they are sometimes taken on a chronic basis as well, 
for example, some antibiotics are taken for extended periods of 
time for acne.139  The selected pharmacies have agreed not to ship 
prescription medicines to United States customers if it is clear that 
the prescription medicines are meant to treat acute conditions.140  
The list of prescription medicines included was further limited 
because the state did not include those prescription medicines that 
were: 
1.  Controlled substances such as narcotics, 
benzodiazepines (Valium and related), barbiturates, 
anabolic steroids, amphetamines, etc.  Reputable 
Canadian pharmacies such as those selected for affiliation 
with RxConnect will not ship controlled substances.141 
2.  Medications with special handling requirements such 
as those needing refrigeration.142 
3.  Medications for which there is not an FDA-approved 
equivalent in the United States (such as those prescription 
medicines that are either available generically in Canada, 
but are not available generically in the United States, or, 
those prescription medicines available in Canada that are 
not available at all in the United States).143 
4.  Medications that contain a level of active ingredient 
different in the United States version than in the 
Canadian version.  For example, the Canadian version of 
Allegra 24 Hour contains less fexofenadine, an 
antihistamine, than the United States version and is not 
listed on RxConnect.144 
 
 137. Compare id. at 3, with Medicine Search, Minnesota RxConnect, available at 
http://rxconnect.dhs.state.mn.us/Medicines.aspx (last visited Feb. 14, 2005) 
(comparing prescription medicines ordered in GAO investigation and those listed 
on MinnesotaRxConnect.com).   
 138. Internal Memorandum from Cody Wiberg, Pharmacy Program Manager 
Minnesota Department of Human Services, to Kevin Goodno, Commissioner, 
Minnesota Department of Human Services (on file with author). 
 139. Id. 
 140. Id. 
 141. Id. 
 142. Id. 
 143. Id. 
 144. Id. 
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Unlike some states that have pursued similar programs to 
RxConnect that have linked their websites directly to Canadian 
pharmacies,145 RxConnect does not use direct links, so the state can 
control all the information provided on the website regarding the 
participating pharmacies, the prescription medicines offered, and 
pricing.  This allows the state to control for content and also to 
control for compliance with the program requirements. 
By restricting the prescription medicines included in 
RxConnect, controlling the information listed on RxConnect, and 
limiting RxConnect to prescription medicines that are approved 
for use in Canada or the United States, RxConnect adds an 
additional layer of protection for Minnesota consumers who want 
to purchase safe and effective prescription medicines from Canada. 
C. Some Prescription Medicines Cost Less in Canada 
The perception of many is that all prescription medicines 
purchased from Canada are less expensive than the comparable 
product offered in the United States.  This is clearly not true.  
Likewise, some would have you believe that any savings a consumer 
would see in Canada is negligible or can easily be offset through 
use of generics or therapy modification.  For example, sometimes 
consumers can reduce their prescription medicine costs by 
substituting brand name prescription medicines for generics, over-
the-counter, or lower dosage medicines.  This may work in some 
cases, but not in all cases. 
As a rule of thumb, brand name prescription medicines are 
cheaper in Canada than the United States; generic prescription 
medicines are less expensive in the United States than Canada; 
and, United States generic prescription medicines, when available, 
are less expensive than either the brand name prescription 
medicines or the Canadian generics.  This rule of thumb has 
exceptions.  For example, the generic prescription medicine 
tamoxifen, which is used in the treatment of breast cancer, is less 
expensive when purchased from the Canadian pharmacies 
affiliated with RxConnect.  A consumer can purchase sixty ten-
 
 145. See, e.g., State of North Dakota website, at http://www.govenor 
.state.nd.us; State of New Hampshire website, at http://www.state.nh.us/governor 
/prescription-drug.html (last visited Mar. 5, 2005).  See generally Congressman Gil 
Gutknecht, Prescription Drug State Information, at http://www.gil.house.gov/issues/ 
pdrugs/ stateinfo.htm (last visited Mar. 5, 2005) (listing states that have or are 
proceeding to implement programs to import drugs). 
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milligram tablets of tamoxifen from the Canadian pharmacies for 
about $33, including shipping, as compared to $66 as listed on the 
website of a large U.S. pharmacy chain.146  In contrast, if purchased 
as a prescription from a Canadian pharmacy, the brand name drug 
Claritin would be more expensive than purchasing the medication 
over-the-counter in the United States.147  Accordingly, it is 
important for the consumer to compare both prescription 
medicine prices between the Canadian pharmacy and the 
American pharmacy and also among Canadian pharmacies and 
among American pharmacies because prices vary. 
To help consumers, RxConnect not only provides information 
on Canadian pharmacies, but also includes information on state 
prescription medicine programs for low-income people, a state-
sponsored information line that provides assistance in navigating 
the various free prescription medicine programs run by the 
pharmaceutical companies and the new Medicare drug discount 
cards, how to be a smart prescription medicine shopper, and 
various strategies on how to reduce prescription medicine costs.148 
Of the prescription medicines initially listed on RxConnect 
about eighty-five percent are less expensive in Canada than in the 
United States, with the remaining fifteen percent being more 
expensive in Canada.149  The statistics on the prescription 
medicines being purchased through RxConnect indicate that 
consumers are aware of these price differences as the prescription 
medicines most commonly purchased are those with the greatest 
savings compared to the United States prices.150  Most of the 
prescription medicines that are more expensive in Canada will be 
removed from RxConnect in future updates as they offer limited 
value to the consumer and are rarely ordered. 
Through January of 2005, RxConnect had 174,599 website 
 
 146. Information provided by Cody Wiberg, Pharmacy Program Manager, 
Minnesota Department of Human Services (on file with author).  Tamoxifen can 
be purchased for $42.98, $35.38 or $23.87 from various Canadian pharmacies.  Id.  
The same dosage is listed on the Walgreens website for $65.99.  Walgreens.com, 
Tamoxifen, 10 mg. tablets, at http://www.walgreens.com/library/finddrug/ 
druginfo1.jhtml?id=15379 (last visited Jan. 26, 2005). 
 147. Wiberg, supra note 146. 
 148. Website of the Minnesota RxConnect Program, Minnesota Department of 
Human Services, at http://www.minnesotarxconnect.com (last visited Jan. 26, 
2005). 
 149. See id. 
 150. Id. 
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visits and over 9000 orders have been filled.151  The assumption 
when the program was established was that the people most likely 
to take advantage of the program were those individuals who were 
already purchasing their prescription medicines from unknown 
mail-order or other discount pharmacies.  Minnesota RxConnect 
was established to provide those individuals with information on 
Canadian pharmacies that had been inspected and had agreed to 
follow certain safe practices. 
V. ADVANTAGE-MEDS 
Phase II of the Minnesota plan provides access to low-cost, 
Canadian prescription medicines for Minnesota state employees.  
Advantage-Meds was launched in May 2004.152  Advantage-Meds 
built on the work done in setting up and choosing vendors for 
RxConnect.  One of the RxConnect pharmacies was selected by the 
Minnesota Department of Employee Relations (DOER) to work 
with its health plan in establishing a state employee program. 
DOER identified a list of forty-seven prescription medicines 
that would provide substantial savings to both the state and its 
employees if employees purchase them from the Canadian 
pharmacy.153  The employee benefits if he or she orders a ninety-
day supply of a selected prescription medicine because the state 
waives the employee’s $15 per prescription co-pay.154  This could 
result in up to a $180 per year per prescription savings for the 
employee.155  The state projects that its savings will be about $1.4 
million per year.156 
The process for ordering is similar to the process for 
RxConnect, except that the state health plan makes payment 
directly to the Canadian pharmacy rather than having the 
employee make the payment and then seek reimbursement from 
the plan.  At the end of 2004, more than 1800 state employees had 
signed up for the program and more than 3100 prescriptions have 
 
 151. Id. 
 152. Press Release, Tim Pawlenty, Governor of Minnesota, Governor Pawlenty 
Launches Phase Two of Rx Drug Importation: State Employee Website (May 13, 
2003) (on file with author). 
 153. Id. 
 154. State of Minnesota, Department of Employee Relations, Canadian 
Prescription Drug Plan for Minnesota State Employees and Dependents, available at 
http://www.advantage-meds.state.mn.us/Factsheet.pdf (last visited Jan. 26, 2005). 
 155. Id. 
 156. Id. 
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been filled.157 
VI. PHASE III PILOT PROJECT 
Although DHS has had exploratory discussions with the FDA 
regarding a pilot program in Minnesota that would allow the 
inclusion of Minnesota pharmacies in the ordering of prescription 
medicines from Canada, no definitive agreement has been 
reached. 
VII. CONCLUSION 
Governor Pawlenty has recognized the reality that many 
Minnesotans purchase prescription medicines from unknown mail-
order pharmacies that hold themselves out as legitimate operators 
selling Canadian approved prescription medicines.  This 
recognition led to the launch of RxConnect which is consistent 
with federal law and the duties of the state to provide for the safety 
of its citizens.  Minnesota provided for the safety of its citizens by 
inspecting Canadian pharmacies to ensure their legitimacy and 
compliance with applicable laws and safe operating procedures and 
then shared that information with its citizens through RxConnect.  
More specifically, Minnesota took steps to ensure that prescription 
medicines ordered from the RxConnect pharmacies were approved 
for distribution in Canada.  Further, Minnesota verified that the 
RxConnect pharmacies were licensed and that the professionals 
who worked for them were licensed and in good standing.  In other 
words, through RxConnect, Governor Pawlenty put a program in 
place to provide Minnesota consumers who choose to purchase 
prescription medicines from Canada access to medicines that are, 
in the words of the FDA, “safe and effective.” 
Minnesota has been a leader in addressing the challenges of 
keeping prescription medicines affordable for Minnesotans and 
controlling overall health care costs.  Sometimes these challenges 
seem daunting, even impossible, but in the words of Franklin 
Delano Roosevelt, as quoted by Governor Pawlenty at a 
congressional hearing on importation, “It is common sense to take 
a method and try it; if it fails, admit it frankly and try another.  But 
 
 157. State of Minnesota, Department of Employee Relations, Advantage Meds 
Activity (Jan. 2004), available at http://www.advantage-meds.state.mn.us/ 
Activity.pdf (last visited Jan. 26, 2005). 
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above all, try something.”158  Minnesota was the first state in the 
nation to establish a program such as RxConnect.  Minnesota was 
also the first state in the nation to implement a program for its 
employees to purchase lower cost medications from Canada.  From 
the Pawlenty Administration’s perspective, Minnesota RxConnect 
and Advantage-Meds have proven to be effective in helping 
Minnesotans, and state government, save on the cost of high-
quality, safe prescription medicines.  Now it is time to try 
something else, such as Phase III of Governor Pawlenty’s plan, 
because a more widespread utilization of Canadian-supplied 
prescription medicines, through wholesale importation by 
Minnesota pharmacies, would benefit Minnesota consumers and 
the state’s health care costs. 
 
 
 158. Tim Pawlenty, Governor of Minnesota, Testimony to the Congressional 
Prescription Drug Access Coalition hearing in Boston, MA (Oct. 28, 2003) 
(transcript available at http://www.governor.state.mn.us/Tpaw_View_DF_Article. 
asp?artid=654). 
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